Ashrafkhorasani Maryam, Besharati Sajad, Mohammadzadeh Vahid, Zou Jane, Figueroa Judy, Mohammadi Masood, Nouri-Mahdavi Kouros
Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; Department of Ophthalmology, University of Louisville, Louisville, Kentucky.
Ophthalmol Glaucoma. 2025 Mar-Apr;8(2):117-125. doi: 10.1016/j.ogla.2024.11.004. Epub 2024 Nov 12.
To test the hypothesis that a summary index derived from the central 12 points of the 24-2 visual field (12-point mean deviation [MD12]) could provide complementary information to that provided by the 24-2 visual field (VF) mean deviation (24-2 MD).
Longitudinal observational study.
One hundred twenty-five eyes (125 patients) with central damage or moderate to severe glaucoma from the Advanced Glaucoma Progression Study with ≥ 4 pairs of 10-2 and 24-2 Swedish Interactive Thresholding Algorithm standard VFs.
Baseline 10-2 and 24-2 VF dates were within 6 months, and the remaining pairs of VF tests were done in the same session. The MD12 index was calculated by averaging total deviation values from the central 12 points of 24-2 VF. Simple linear regression of MD against time was used to estimate 24-2 MD, 10-2 MD, and MD12 rates of change (RoC). Progression at the final follow-up visit was defined as a RoC < 0 dB/year with P < 0.05 for any summary index with confirmation.
Proportion of progressing eyes based on 24-2 MD, 10-2 MD, and MD12 RoC.
The average (standard deviation) baseline 24-2 and 10-2 MD were -9.0 ± 6.2 and -8.5 ± 5.4 dB, respectively. The mean follow-up time was 5.7 (±1.6) years. The three summary indices were highly correlated at baseline: r = 0.62 (95% confidence interval: 0.52-0.74) between 10-2 MD and 24-2 MD, 0.84 (95% confidence interval: 0.78-0.90) between MD12 and 24-2 MD, and 0.86 (95% confidence interval: 0.80-0.92) between 10-2 MD and MD12. The corresponding correlations between RoC were weaker: r = 0.41 (95% confidence interval: 0.37-0.45), 0.80 (95% confidence interval: 0.78-0.82), and 0.49 (95% confidence interval: 0.45-0.53). Glaucoma progression was detected in 29 (23.2%), 22 (17.6%), and 23 eyes (18.4%) based on the 24-2, 10-2, and MD12 RoC, respectively; 7 eyes (9.6%) exhibited progression based on MD12 RoC and not with 24-2 MD; only 3 of these eyes progressed according to 10-2.
MD12 RoC and detection rates have a low level of agreement with those of 10-2 and hence do not replace the need for 10-2 VF MD to monitor central damage.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
检验以下假设，即从24-2视野中央12个点得出的汇总指数（12点平均偏差[MD12]）能够为24-2视野（VF）平均偏差（24-2 MD）提供补充信息。
纵向观察性研究。
来自高级青光眼进展研究的125只眼（125例患者），患有中央损害或中度至重度青光眼，有≥4对10-2和24-2瑞典交互式阈值算法标准视野。
基线10-2和24-2视野检查日期在6个月内，其余视野检查对在同一检查时段完成。MD12指数通过对24-2视野中央12个点的总偏差值求平均来计算。采用MD随时间的简单线性回归来估计24-2 MD、10-2 MD和MD12的变化率（RoC）。最终随访时的进展定义为RoC<0 dB/年，且任何汇总指数的P<0.05并有确认。
基于24-2 MD、10-2 MD和MD12 RoC的进展眼比例。
基线时24-2和10-2 MD的平均（标准差）分别为 -9.0±6.2和-8.5±5.4 dB。平均随访时间为5.7（±1.6）年。三个汇总指数在基线时高度相关：10-2 MD与24-2 MD之间r = 0.62（95%置信区间：0.52 - 0.74），MD12与24-2 MD之间r = 0.84（95%置信区间：0.78 - 0.90），10-2 MD与MD12之间r = 0.86（95%置信区间：0.80 - 0.92）。RoC之间的相应相关性较弱：r = 0.41（95%置信区间：0.37 - 0.45）、0.80（95%置信区间：0.78 - 0.82）和0.49（95%置信区间：0.45 - 0.53）。基于24-2、10-2和MD12 RoC，分别在29只眼（23.2%）、22只眼（17.6%）和23只眼（18.4%）中检测到青光眼进展；7只眼（9.6%）基于MD12 RoC显示进展而24-2 MD未显示进展；其中只有3只眼根据10-2显示进展。
MD12 RoC和检测率与10-2的一致性较低，因此不能替代10-2视野MD来监测中央损害。
在本文末尾的脚注和披露中可能会发现专有或商业披露信息。
